Rhaeos

Rhaeos is developing FlowSense, a noninvasive, wireless skin patch designed to monitor fluid flow subdermally in real time. Initially targeting hydrocephalus, FlowSense enables bedside and at-home assessment of cerebrospinal fluid (CSF) flow in shunts without the need for capital equipment. By providing a noninvasive alternative to current monitoring methods, FlowSense aims to reduce emergency visits and surgical interventions for hydrocephalus patients. The technology has received FDA Breakthrough Device designation.